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Abstract
Background: Although altered lipid metabolism has been extensively implicated in the pathogenesis of Alzheimer disease
(AD) through cell biological, epidemiological, and genetic studies, the molecular mechanisms linking cholesterol and AD
pathology are still not well understood and contradictory results have been reported. We have used a Mendelian
randomization approach to dissect the causal nature of the association between circulating lipid levels and late onset AD
(LOAD) and test the hypothesis that genetically raised lipid levels increase the risk of LOAD.
Methods and Findings: We included 3,914 patients with LOAD, 1,675 older individuals without LOAD, and 4,989 individuals
from the general population from six genome wide studies drawn from a white population (total n=10,578). We constructed
weighted genotype risk scores (GRSs) for four blood lipid phenotypes (high-density lipoprotein cholesterol [HDL-c], low-density
lipoprotein cholesterol [LDL-c], triglycerides, and total cholesterol) using well-established SNPs in 157 loci for blood lipids
reported by Willer and colleagues (2013). Both full GRSs using all SNPs associated with each trait at p,561028 and trait specific
scores using SNPs associated exclusively with each trait at p,561028 were developed. We used logistic regression to investigate
whether the GRSs were associated with LOAD in each study and results were combined together by meta-analysis. We found no
association between any of the full GRSs and LOAD (meta-analysis results: odds ratio [OR]= 1.005, 95% CI 0.82–1.24, p=0.962 per
1 unit increase in HDL-c; OR=0.901, 95% CI 0.65–1.25, p=0.530 per 1 unit increase in LDL-c; OR=1.104, 95% CI 0.89–1.37,
p=0.362 per 1 unit increase in triglycerides; and OR=0.954, 95% CI 0.76–1.21, p=0.688 per 1 unit increase in total cholesterol).
Results for the trait specific scores were similar; however, the trait specific scores explained much smaller phenotypic variance.
Conclusions: Genetic predisposition to increased blood cholesterol and triglyceride lipid levels is not associated with
elevated LOAD risk. The observed epidemiological associations between abnormal lipid levels and LOAD risk could
therefore be attributed to the result of biological pleiotropy or could be secondary to LOAD. Limitations of this study
include the small proportion of lipid variance explained by the GRS, biases in case-control ascertainment, and the limitations
implicit to Mendelian randomization studies. Future studies should focus on larger LOAD datasets with longitudinal
sampled peripheral lipid measures and other markers of lipid metabolism, which have been shown to be altered in LOAD.
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Introduction
Altered lipid metabolism has been extensively implicated in late
onset Alzheimer disease (LOAD) pathogenesis but the molecular
basis of this relationship is not well understood. Cell biological
studies support a critical involvement of lipid raft cholesterol in the
modulation of Ab precursor protein processing by b-secretase and
c-secretase resulting in altered Ab production (reviewed in [1]). In
the brain, apolipoprotein E (APOE) acts as the major cholesterol
transporter, taken up into neurones via low density lipoprotein
receptor (LDLR) family members. APOE is lipidated by the
cholesterol transporter ABCA1 in astrocytes and its correct
lipidation is necessary for binding and clearance of Ab from the
brain [2]. Additionally, APOE is a crucial regulator of triglyceride
metabolism throughout the body [3].
In addition to the APOE gene, many of the LOAD
susceptibility loci identified through genome wide association
(GWA) studies and meta-analyses are also involved in lipid
metabolism [4–6]. For example, CLU, or APOJ, is the second
main lipoprotein in the brain after APOE; PICALM and BIN1 are
implicated in receptor mediated endocytosis; and ABCA7 is
involved in the efflux of lipids from cells to lipoproteins.
Epidemiological studies have shown associations between high
cholesterol levels in midlife and LOAD risk [7–9], and statins have
been shown to have a protective effect against the development of
dementia [10–12]. However contradictory results have also been
reported, with other epidemiological studies reporting no associa-
tion of lipid levels on LOAD risk [13,14] or a decline in cholesterol
levels before the onset of dementia [12,15] and randomized control
trials overall finding no benefit of statin treatment [16–19].
The aim of this study was to examine whether genetic
predisposition to increased blood cholesterol and triglyceride
levels (i.e., dyslipidemia) plays an aetiological role in LOAD.
Consequently genetic risk variants, which affect lipid metabolism,
would influence risk of LOAD through changes in lipid levels.
This is the first genetic study, to our knowledge, to investigate
the causal nature of the relationship between lipid dysregulation
and LOAD using such an approach, the results of which have the
potential for public health interventions.
Methods
Ethical approval was obtained for all cohorts in the corre-
sponding centres.
We have employed a Mendelian randomization approach
(Figure 1), which uses the principle that the random meiotic
assortment of genotypes is independent of confounding non-
genetic factors or disease processes.
Since the effects of individual loci identified through GWA
studies and meta-analyses are small, we examined whether
genotype risk scores (GRSs), based on the joint additive effect of
157 well-established independent loci involved in lipid metabolism
(p,561028) in a recent GWA study and meta-analysis by Willer
and colleagues [20] of 188,577 participants, influence LOAD, in a
sample of 10,578 participants, comprising 3,914 patients with
LOAD (cases), 1,675 older individuals without LOAD, and 4,989
individuals from the general population. We analysed GRS for the
phenotypes blood high-density lipoprotein cholesterol (HDL-c),
plasma low-density lipoprotein cholesterol (LDL-c), total plasma
cholesterol (TC), and plasma triglycerides (TG).
Study Design and Participants
This study utilized data from participants from three indepen-
dent study groups composed of six GWA studies. All individuals
included in this study have provided written informed consent.
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The first group was the Medical Research Council (MRC)-
Wellcome Trust Case Control Consortium (WTCCC2) group
including 3,292 individuals with LOAD (cases), 1,223 older
individuals without LOAD (controls), and 5,074 individuals from
the general population (population controls), consisting of four
cohorts: 3,216 cases and 1,165 controls from the GERAD1 cohort
(Genetic and Environmental Risk for Alzheimer’s disease) consor-
tium [4] genotyped on the Illumina 610-quad chip; 18 LOAD cases
and ten controls from the MRC Brain cohort, genotyped on the
Illumina 666W-Quad chip; and 5,074 population controls from the
WTCCC2 publically available control cohorts (www.wtccc.org.uk/
ccc2/: the 1958 British Birth Cohort [WTCCC2 1958 BC] and UK
Blood Service Collection [WTCCC2 National Blood Donors
(NBS)]), genotyped on the Illumina 1.2M chip.
The second group was the Institute of Psychiatry Plus (IOP+)
group including 450 individuals who were cases, and 365
individuals who were controls, from the AddNeuroMed (ANM)
cohort (362 cases, 237 controls) [21], and individuals from the
Dementia Case Register (88 cases and 128 controls). These groups
were genotyped on the Illumina 610-Quad chip in two different
batches and merged together (batch 1: 222 cases, 111 controls;
batch 2: 228 cases and 254 controls). Additionally, batch 1
contained 99 and batch 2 contained 78 individuals with mild
cognitive impairment (MCI).
The third group consisted of 330 individuals who were cases
and 187 who were controls obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu),
genotyped on the Illumina 610-Quad chip.
Further details on all groups and cohorts are found in Text S1.
All individuals contributing data for this study were white. All
individuals with LOAD (cases) met criteria for either probable
(NINCDS-ADRDA, DSM-IV) or definite (CERAD) AD [22]. All
non-population individuals who were controls were screened for
dementia using the MMSE or ADAS-cog, or were determined to be
free from dementia at neuropathological examination or had a
Braak score #2.5. All individuals with LOAD (cases) had an age of
onset $60 years and controls were $60 years at examination. The
58BC individuals (population controls) were around 54 years at the
age of collection and no age was available for the NBS cohort.
Because genotype data were used from multiple sources, stringent
quality control (QC) filters were applied since differential genotyping
error rates between groups could result in spurious associations when
the data are combined [23,24]. These filters were applied separately
to each of these groups to remove poorly performing samples
followed by SNP QC on each group. Prior to individual and SNP
QC the MRC brain cohort was merged with the GERAD1 cohort
after removing symmetric SNPs and flipping SNPs with opposite
strands (from now on referred to as the MRC cohort).
GWA Quality Control
Individual QC filters in the MRC, WTCCC2 58C, WTCCC2
NBS, IOP+, and ADNI datasets were applied using tools
implemented in PLINK [25]. QC for the IOP+ group took place
separately for the two different batches.
Briefly, we excluded individuals with (a) gender mismatches
(M.0.8, male; F,0.2, female rule in PLINK; (b) an individual call
rate #98%; (c) individuals with autosomal heterozygosity outside
64 standard deviation (SD) of the mean heterozygosity; and (d)
duplicates and cryptically related by calculating identity by descent
(IBD) estimates for all possible pairs of individuals in PLINK and
removing one of each pair with an IBD estimate $0.1875 (the
level expected for second cousins). Each of the five datasets were
then merged with genotypes from 210 unrelated European (CEU),
Asian (CHB and JPT), and Yoruban (YRI) samples from the
HapMap project (www.hapmap.org). Following removal of SNPs
in extensive regions of linkage disequilibrium and pruning of SNPs
if any pair within a 50-SNP window had r2.0.2, principal
components analysis (PCA) as implemented in SMARTPCA
[26] was used to infer continuous axes of genetic variation.
Eigenvectors were calculated on the basis of the linkage
disequilibrium (LD)-pruned subsets of each of the merged datasets
to identify and then remove individuals of divergent ancestry
displayed by plotting the first two principal components and using
K-means clustering.
EIGENSOFTplus [27] was then applied to each of the datasets
to additionally correct for population substructure, and genetic
outliers defined as individuals whose ancestry is at least 6 SDs from
the mean on one of the top ten axes of variation were removed.
Four principal components explained most of the variation in the
IOP+ and ADNI datasets and were extracted in order to be used
as covariates in further analyses. Since the MRC and WTCCC2
datasets were merged at a later stage, extraction eigenvectors took
place after sample merging.
SNP Quality Control
Because of unresolved genotype-calling issues with a proportion
of SNPs on the sex chromosomes in the 610 cohort, only
autosomal SNPs were included in SNP QC for all cohorts. Briefly
SNP QC took place (a) including SNPs with MAF.1%; (b)
including SNPs with missingness ,3% if MAF$0.05 and SNPs
with missingness ,1% if MAF,0.05, and (c) excluding SNPs with
HWE p#161024 in controls.
Imputation
Since some of the SNPs to be used in this study were not
included on the Illumina platform or failed QC, imputation took
place using IMPUTE_2.2.2 [28] and the 1000G phase1 integrated
reference panel (April 2012, National Center for Biotechnology
Information [NCBI] build 37) (Text S1).
Figure 1. Possible mechanisms through which susceptibility
genes act on lipid blood levels and LOAD. (a) Relationship
between lipid SNPs and altered blood lipid levels; (b) relationship
between altered blood lipid levels and LOAD; and (c) relationship
between SNPs associated with altered lipid levels and LOAD.
doi:10.1371/journal.pmed.1001713.g001
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Final QC Steps
The MRC dataset was then merged together with the
WTCCC2 58C and WTCCC2 NBS datasets and the two IOP+
batches were also merged together. Symmetric SNPs were
excluded and PLINK was used to identify incorrect strand
assignment by utilizing LD patterns and exclude SNPs where the
strand may have been incorrectly assigned between the three
datasets. The merged datasets underwent an additional round of
individual QC as described above and EIGENSOFTplus was
applied to correct for population substructure as described. Four
principal components explained most of the variation in the data
and were extracted to be used as covariates in further analyses.
Final QC resulted in 3,234 individuals with LOAD (cases), 1,175
individuals who were controls, and 4,989 individuals who were
population controls from the MRC-WTCCC2 group (n=9,398);
350 individuals with LOAD (cases) and 313 individuals who were
controls from IOP+ group (n=663); and 330 individuals with
LOAD (cases) and 187 individuals who were controls from the
ADNI group (n=517), a total of 10,578 individuals included in all
analyses.
Outcomes
The main outcome of the study was LOAD status (dichoto-
mous) in the 10,578 individuals included in analyses with available
imputed data.
A total of 227 individuals with LOAD (cases) and 196
individuals who were controls of the ANM cohort of the IOP+
group had HDL-c, LDL-c, TC, and TG serum levels (mmol/l)
available. Additionally, lipid serum data were also available for
127 individuals with MCI from the ANM cohort who had
undergone GWA/imputation together with LOAD cases and
controls of the ANM cohort.
Genotype Risk Score Construction
Genotype scores were calculated for each of the four lipid
phenotypes (TC, LDL-c, HDL-c, and TG) using the SNPs at 157
independent loci associated with plasma lipids at (p,561028) as
reported by Willer and colleagues [20]. To avoid any spurious
associations the rs4420638 SNP within the APOE locus was
excluded from further analyses and we used SNAP [29] to
investigate linkage disequilibrium patterns between the blood lipid
SNPs and SNPs associated with LOAD in the latest LOAD meta-
analysis finding no significant linkage disequilibrium (r2,0.2). We
also excluded SNP rs581080 in the TTC39B locus, SNP rs9411489
in the ABO locus, and SNP rs3177928 in the human leukocyte
antigen (HLA) locus because they failed genotyping/imputation
QC and we could not find any successfully genotyped/imputed
SNPs with r2.0.8 to use as proxies. We initially constructed a GRS
that included all SNPs associated with each target lipid trait at a pre-
specified p-value threshold of p,561028 (full score); we therefore
used 69 HDL-c SNPs, 55 LDL-c SNPs, 40 TG SNPs, and 70 TC
SNPs for the construction of the respective full score. Since one of
the prerequisites for a Mendelian randomization study is that there
must not be pleiotropic effects of the genetic variants of interest and
since there is a considerable overlap of SNPs associated with each
trait (Figure S1), a second score was constructed using SNPs
exclusively associated with the target lipid trait at a p-value
threshold of p,561028 (trait specific score); we therefore used 45
HDL-c SNPs, nine LDL-c SNPs, 18 TG SNPs, and 18 TC SNPs for
the construction of the respective trait specific score.
Full and trait specific risk scores (GRSs) were constructed in
PLINK using the –score option [25] and assuming that each SNP
in the panel acts independently and contributes to the risk of
LOAD in an additive manner.
The weighted risk scores were constructed by multiplying each
SNP by its relative effect size (b-coefficient) obtained from Willer
and colleagues [20] and selecting as the ‘‘risk’’ allele that was
associated with increased LDL-c, TG, and TC levels and
decreased HDL-c levels.
We summed the products of each score and divided them by the
number of non-missing SNPs genotyped/imputed for each
individual, creating a score per non missing SNP. The GRSs
were further standardized and results are expressed per 1 SD of
each GRS.
Individuals missing $5% of the SNPs for each GRS were
excluded. Table S1 presents the details of the SNPs used for the
construction of the GRSs.
Statistical Analyses
All analyses were performed in STATA 12 (Stata Statistical
Software: Release 12, StataCorp LP). Power calculations were
performed using QUANTO (http://hydra.usc.edu) to estimate the
power of this study.
Association of Serum Lipid Levels with Each Lipid
Genotype Risk Score and LOAD Status
Serum lipid levels (mmol/l) available for the ANM subset were
converted to mg/dl by multiplying HDL-c, LDL-c, and TC by
38.67 and TG by 88.57. Each lipid was regressed against age, age-
squared, and gender, and the residuals were inverse normal
transformed.
Linear regression analyses were performed using the inverse
normal lipid traits values as the dependent variable and the
respective GRS as the independent variable (first stage equations)
using the 227 LOAD cases and 196 elderly controls from the
ANM study. To increase power we also included the 127
individuals with MCI. These first stage equations were later used
to weigh the association of each GRS with LOAD status. We also
used logistic regression analyses to investigate the association of the
inverse normal transformed lipid traits levels with LOAD status in
the ANM cohort.
Instrumental Variable Analyses
We used instrumental variable (IV) estimators to quantify the
strength of the causal association between lipid traits and LOAD.
We used two different procedures for our IV analysis.
Instrumental variable analysis using individual level
data. For the main analysis of this study we investigated the
association of each of the four lipid trait GRSs with LOAD.
Logistic regression analyses were used to test for the association of
each GRS with LOAD separately in each group adjusting for the
first four PCS extracted during QC for each group. It was not
possible to include a covariate for each chip for the MRC-
WTCCC2 group as only population controls were genotyped on
the 1.2 M chip. Similarly, it was not possible to include a covariate
for each of the four cohorts of the MRC-WTCCC2 group, as the
WTCCC2 groups included only population controls. The IOP+
cohort was adjusted for an additional covariate denoting
genotyping batch. The instrumental variable estimate for each
lipid trait was obtained by dividing the LOAD-GRS log OR
estimate of each group (second stage equation) with the respective
beta estimate of the linear regression of each lipid trait against the
respective GRS (lipid trait-GRS) from the 550 individuals of the
ANM study with serum lipid data available (first stage equation).
To take into consideration the uncertainty in both the LOAD-
GRS and the lipid trait-GRS associations we used the delta
method to estimate the standard errors of the instrumental
Association between Genetic Dyslipidemia and AD
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variable ratio estimates [30]. The resulting estimates were pooled
together using inverse-variance fixed effects meta-analysis. We
acknowledge that our instrumental variable (lipid trait-GRS
associations) is calculated using only 550 participants from the
ANM study. A recent study [31] has demonstrated that generating
exposure data (such as lipid trait-GRS data) for a subset of
participants rather than all participants in the study or from
participants who are obtained from independent non-overlapping
samples drawn from the same population does not substantially
decrease power when the instrumental variable is relatively strong.
An instrumental variable is considered strong when the first stage
equation R2<2.5% and, as demonstrated by Pierce and Burgess
[31], full power is achieved for an R2$1.5% with exposure data
for ,20% of the total sample. Additionally, loss in power is very
small when the subsample/independent sample is 5%–10% of the
total study sample. In our study groups, exposure data for the lipid
trait-GRS association is available for 6% of the sample size of the
MRC-WTCCC2 group (independent sample), for 83% of the
IOP+ group (sub-sample), and for more participants than those in
the ADNI group (independent sample). We have therefore used
the instrumental variable estimate when the first stage equation for
the four traits was R2$1.5%.
Instrumental variable analysis using summary data. A
second instrumental variable approach was used in order to verify
findings of the instrumental variable approach using individual
level data and to be used alternatively when the lipid trait-GRS
first stage association was R2,1.5%. This approach was based on
calculating the instrumental variable estimate using summary data
approach, which has been shown to be similarly efficient to
individual level data analyses [32]. Logistic regression analyses
were used to test for the association of each lipid trait SNP with
LOAD separately in each group adjusting for covariates as
detailed above. As in the case of the GRS, we selected as the ‘‘risk’’
allele that which was associated with increased LDL-c, TG, and
TC levels and decreased HDL-c levels. The instrumental variable
estimate from summary data for each lipid trait was then obtained
by summing the log OR of the individual logistic regression
analyses of all SNPs associated with each plasma lipid trait and
weighing this with the summary of the estimates of each SNP with
the respective trait obtained from Willer and colleagues [20] in an
inverse-variance weighted meta-analysis. The delta method was
used to approximate the standard error [32].
Instrumental variable analysis was conducted using both full
and trait specific scores.
Additional Analyses
Additional analyses were performed excluding the population
controls from the MRC-WTCCC2 group and adjusting for age at
baseline visit, gender, and number of APOE e4 alleles (Text S1).
Results
The sample characteristics are presented in Table 1. SNPs
details, including their minor allele frequency and association with
LOAD in each group, are presented in Table S1.
Association of Blood Lipid Levels with the GRS and with
LOAD in the ANM Cohort
The four full scores strongly correlated with the corresponding
lipid trait phenotype; however, we observed no correlation
between the trait specific scores and the corresponding lipid traits
(Table 2) in the ANM individuals. We additionally observed no
association between measured lipid levels and LOAD (Table 3) for
this cohort.
Expected Effect Size and Power of the Study
Using two epidemiological studies that have shown positive
associations between cholesterol levels and LOAD and the observed
associations between the weighted TC GRS and TC levels in the
ANM sample, we estimated the expected effect sizes (Figure 1) and
the power of our study. According to Whitmer and colleagues [7]
midlife high TC levels ($240 mg/dl) were associated with increased
LOAD risk, hazard ratio [HR]=1.42 (95% CI 1.22–1.66), after
adjusting for other cardiovascular risk factors and, according to
Kivipelto and colleagues [8], high TC levels ($6.5 mmol/l, i.e.,
251.35 mg/dl) were associated with increased LOAD risk,
OR=2.8 (95% CI 1.2–6.7) (Figure 1b). We dichotomised serum
TC levels in the ANM subset according to these two studies and
estimated their association with the TC GRS. The OR of high TC
levels in our sample using theWhitmer and colleagues [7] cut-off ($
6.2 mmol/l) was OR=1.679 (95% CI 1.35–2.10, p=4.0161026)
and the OR of high TC levels using Kivipelto and colleagues [8]
cut-off ($6.5 mmol/l) was OR=1.71 (95% CI 1.34–2.20,
p=1.9261025) per GRS SD (Figure 1a) for the full GRS. This
means that, if the weighted TC GRS is associated with LOAD
through its association with TC levels we would expect the
association of the GRS with LOAD (Figure 1c) to be between
OR=1.19 (95%CI 1.06–1.46) and OR=1.73 (95%CI 1.06–4.48).
Our sample size of.10,000 participants and the GRS approach we
employed gave us .99% power to capture these ORs.
Association of the Genotype Risk Scores with LOAD
Status
Instrumental variable analysis for the four full GRSs was
performed using individual level data since the association of the
four full GRSs with the corresponding lipid produced R2.0.015
(first stage equation). We found no association between any lipid
traits and LOAD status (Figure 2; Table S2). Instrumental
variable results for the four full GRSs using summary data based
on the plasma lipid study by Willer and colleagues [20] were
identical (Figure S2; Table S2).
Since we found no association between the four trait specific
GRSs and the respective serum lipid (Table 2), instrumental
variable analysis for the trait specific scores was performed using
summary data only from Willer et al [20]. We observed a weak
positive association between HDL-c and LOAD status when using
the trait specific score and no associations for the rest of the traits
(Figure 2; Table S2). Results of the logistic regression analyses for
each of the four full and trait specific GRSs against LOAD status
(second stage equations) are presented in Table 4.
Excluding population controls and adjusting for covariates
produced similar results for all analyses (Tables 5 and 6).
Discussion
The aim of this study was to dissect the causal nature of the
association between blood lipid levels and LOAD and to
investigate whether genetic predisposition to dyslipidemia plays
an aetiological role in LOAD. To achieve this we used a
Mendelian randomization approach and we examined the causal
role of HDL-c, LDL-c, TG, and TC in LOAD risk by exploring
the association of GRS based on the additive joint effect of 157
well established genetic loci [20] that influence plasma HDL-c,
LDL-c, TC, and TG levels with LOAD in a sample of .10,000
participants. Full GRSs were constructed including all SNPs
associated with the respective trait at p,561028. Instrumental
variable analysis took place using individual level data and
calculating the instrumental variable estimate by dividing the
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LOAD-GRS estimate for each lipid trait with the respective lipid
trait-GRS estimate for each study and pooling them together using
meta-analysis, when the association of the lipid trait-GRS was
R2.1.5%. Instrumental variable analysis using summary data was
used to verify individual level results and when the lipid trait-GRS
was R2,1.5%. Since one of the prerequisites for a Mendelian
randomization study is that there must not be pleiotropic effects of
the genetic variants of interest, we additionally attempted to dissect
these associations further and we constructed trait specific GRSs
including SNPs associated exclusively with each lipid phenotype.
We found no association between any of the full GRSs and
LOAD risk. Our results suggest that genetically raised HDL-c,
LDL-c, TG, and TC levels are not causally associated with LOAD
risk. Results for the trait specific scores were similar. Although we
observed a positive association between the HDL-C GRS and
LOAD we must acknowledge the large standard error of the
association and that the trait specific score is a weaker instrument.
The 157 loci account approximately for 12%–14% of the variation
of each trait [20]; however, there are no published results of the
trait variance explained by SNPs exclusively associated with each
trait. In our study we observed a clear difference between the full
GRS (R2= 1.8%–4.3%) and the trait specific GRS (R2#0.5%)
highlighting that although the trait specific score had increased
specificity for the target lipid, it is less statistically powerful and
consequently less biologically interpretable. Finally, excluding
population controls and adjusting for covariates produced similar
results.
Clinical Relevance
Altered lipid metabolism has been extensively implicated in AD
pathogenesis through cell biological, epidemiological, and genetic
studies, but the molecular mechanisms linking cholesterol and risk
for AD are still not well understood. This relationship between AD
and altered lipid metabolism is of considerable interest for both
basic scientists and clinicians. This is the first study, to our
knowledge, to model the joint additive effect of lipid associated loci
on LOAD risk using a Mendelian randomization approach.
Therefore this article contributes considerably to research on the
role of lipids in risk for LOAD and has potential for suggesting
novel therapeutic and public health interventions.
Strengths and Limitations
One of the strengths of this study is that genetic variants
combined into a GRS to test for a complex association between
metabolic traits and LOAD in a very large sample using
Mendelian randomization were used. The additive effects of these
SNPs have been found to be highly associated with the extremes of
the distribution for each trait. For example, in a meta-analysis by
Teslovich and colleagues [33] using a smaller number of lipid
associated loci (n=95), the OR of high plasma LDL-c (mean
219 mg/dl) against low plasma LDL-c (mean 110 (mg/dl) for
individuals on the top LDL-c GRS quartile was 12.5 (95% CI 9.1–
17.5, p=1610214). Here, in the subset with serum lipid levels we
observed strong associations between all of the GRSs and the
corresponding serum lipid levels, which are similar to those
previously published for plasma lipid levels. Using two epidemi-
ological studies that have shown positive associations between
HR=1.45 and OR=2.8 (the majority of positive associations
reported are OR/HR between 2 to 3) and the association between
TC GRS and abnormally high serum TC levels in the ANM
cohort, the expected effect sizes in this study were estimated to be
between OR=1.20 and OR=1.70 per GRS SD giving us .99%
power to capture these associations. Using individual level data
and summary data when appropriate, we calculated instrumental
variable estimators assessing the association of the GRS with
LOAD status per increase in 1 lipid unit.
Mendelian randomization studies overcome biases found in
non-genetic studies such as confounding and reverse causation.
For example, epidemiological studies investigating the association
of lipid levels and LOAD can be biased from confounding factors
that may affect lipid levels, from the co-occurrence of other
conditions that may be associated with LOAD such as impaired
Table 2. Association of the four full and trait specific GRSs with the respective serum levels in participants of the ANM cohort.
Trait GRS (n SNPs) ANM (n=550) Respective Serum Lipid
beta 95% CI p-Value R2 F (1,548)
HDL-C Full (69 SNPs) 0.210 0.12–0.30 3.14E206 4.19% 22.2
Trait specific (45 SNPs) 20.016 20.11 to 0.07 7.30E201 0.02% 0.1
LDL-C Full (55 SNPs) 0.136 0.05–0.22 2.19E203 1.83% 9.5
Trait specific (9 SNPs) 20.051 20.14 to 0.04 2.45E201 0.28% 1.4
TG Full (40 SNPs) 0.208 0.12–0.29 2.08E206 4.34% 23.1
Trait specific (16 SNPs) 0.072 20.02 to 0.16 1.15E201 0.50% 2.5
TC Full (70 SNPs) 0.191 0.10–0.28 1.67E205 3.59% 18.9
Trait specific (18 SNPs) 0.054 20.03 to 0.14 2.16E201 0.31% 1.5
beta represents the association of each GRS with 1 unit increase in blood lipid levels. These associations include 127 MCI individuals.
doi:10.1371/journal.pmed.1001713.t002
Table 3. Association of serum lipid levels with LOAD in
participants of the ANM cohort.
Serum Lipid Levels ANM (n=423)
OR 95% CI p-Value
HDL-C 1.045 0.86–1.28 0.659
LDL-C 1.105 0.90–1.35 0.324
TG 0.870 0.71–1.07 0.182
TC 1.071 0.88–1.31 0.505
OR represents the association of 1 unit of each serum lipid with LOAD status.
doi:10.1371/journal.pmed.1001713.t003
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glucose metabolism and obesity, from the type of study performed,
from the fact that the majority of the studies have only used total
cholesterol measurements, from the different blood lipid cut-offs
used for analysis (or their use as continuous variable), and, most
importantly, from the different timing of lipid measurements in
relation to age and disease onset. For example many studies have
been conducted late in the life of the participant when substantial
AD neuropathology may already be present and it is therefore
difficult to determine whether any changes in cholesterol levels are
increasing risk for disease or, conversely, whether the pathophys-
iological changes that accompany AD alter cholesterol levels
(reviewed in [34]). Interestingly, it has been shown that total
cholesterol decreases with age [35], which may reflect ongoing
disease processes and it has been suggested that as blood pressure
and body mass index have been shown to begin to decline several
years before dementia, the same may occur for LDL-c levels,
supporting a role for reverse causation. Indeed, for males in the
Honolulu-Asia study comparing total cholesterol levels across 26
years, an accelerated pre-clinical decline in cholesterol was
observed for those who subsequently developed AD [15]. A recent
study examined serum cholesterol levels and cerebral Ab
measured with carbon C11-labeled Pittsburgh Compound B
(PIB) and found a negative association between HDL-c and global
PIB index and a positive association between LDL-c and global
PIB index [36]. Although these findings are consistent with some
epidemiological and clinical studies, the authors acknowledge that
the measurements are cross-sectional, obtained late in life, and
from a high vascular risk population; hence these associations
could be confounded through reverse causation as other cross
sectional studies. Genetic studies, however, overcome these issues
since they are more likely to reflect lifelong exposure to altered
circulating blood lipid levels.
Our study, similar to other Mendelian randomization studies,
suffers from potential limitations [37–39], which are related to the
validity of the assumptions underlying these studies. The main
assumptions are: (a) independence between instrument and
Figure 2. Results of the meta-analysis pooled estimates for the effect of a 1 unit increase in blood lipid traits on LOAD risk using
instrumental variable analysis (n=10,578). GRSs were calculated using all independent SNPs associated with each trait (full score) and SNPs
associated exclusively with each trait (trait specific score). Full score estimates were derived by weighing the association between GRS and LOAD for
each dataset with the association between GRS and blood lipid trait and pooling them together using inverse-variance fixed effects meta-analysis
and by using the summary method. Restricted score estimates were derived by using the summary method since the trait specific score and blood
lipid estimate was a weak instrument. See Methods for further details.
doi:10.1371/journal.pmed.1001713.g002
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covariates, i.e., that the tested genotypes in the GRS are
randomized; (b) a reliable association between the GRS and the
intermediate phenotype (first stage equation), and (c) lack of
pleiotropy. Although we know that there is no violation of the
second assumption particularly in the case of the full GRS,
possible violations of the first and third assumptions include
population stratification, pleiotropic effects, canalization, epige-
netic effects, and the confounding effect of genes associated with
confounders and outcomes in high linkage disequilibrium with
genotypes. Population stratification is not present in the current
study since a white population has been used and allele frequencies
between the different cohorts are very similar. Additionally,
pleiotropy and the potentially confounding effects of linkage
disequilibrium are likely avoided owing to the use of multiple
genetic variants in the GRS and the use of the trait specific scores.
Nevertheless, canalization cannot be completely excluded as a
limitation of the present study.
Another limitation of our study, linked also to Mendelian
randomization assumption two, is that that serum lipid levels were
only available for a small proportion of the sample (227 LOAD
cases, 196 controls and 127 MCI from the ANM cohort). We used
the 550 participants from ANM dataset to calculate the GRS-lipid
trait association (first stage equation) for the individual level data
instrumental variable analysis in order to derive these estimates
from a sample nested within our total sample. We also used the
550 participants from the ANM cohort in order to infer the
expected association between the GRS with LOAD in our power
analysis, since we could not find any available large published
studies where the same cut-off for cholesterol levels was used when
investigating its association with GRS and with LOAD. We have
to additionally acknowledge that since these estimates are derived
from the ANM cohort they may not apply to the other cohorts.
Although we acknowledge the small number of participants, all
the full GRSs were strongly associated with the respective lipid
with R2= 1.8%–4.3% (strong instruments) and it is shown [31]
that full power is achieved for an R2.1.5% with exposure data for
,20% of the total sample/independent sample and with very
small loss in power when the subsample/independent sample is
5%–10% of the total study sample. Moreover, we acknowledge
that our lipid measurements for the ANM cohort come from
serum as opposed to the Willer and colleagues [20] study which
was based on plasma lipid measurements. Consequently, the
association between the GRS and lipids and the instrumental
variable analysis using individual level data are based on lipid
serum data. On the other hand, our instrumental variable analysis
using summary data is based on plasma lipid data from Willer and
colleagues [20]. The association between the GRS and serum
lipid levels in our sample closely reflect those for plasma in
published studies (for example, Teslovich and colleagues [33]).
Additionally, the suitability of our instruments when R2.1.5%
was verified by performing instrumental variable analysis using
summary data.
Another limitation was that although no association was
observed between the GRS and age in cases or controls suggesting
no survival effect, cases were on average older than controls. We
also included ,6,000 population controls, ,3,000 of whom were
,60 years and could therefore develop AD in the future, and
,3,000 of this group had no age or cognitive level information.
Additionally, samples from the WTCCC2 1958 Birth Cohort were
also included in the Global Lipids Consortium study. However,
when we repeated analyses excluding the population controls,
results were essentially identical. A strength of our large case
control study is that diagnosis of AD is standardised and
performed under a research setting and for a proportion of cases
and cognitively normal elderly controls diagnosis was confirmed
by pathological examination. We must also take into consideration
that case-control studies have the potential for selection or
ascertainment biases in the inclusion of cases with dyslipidemia
associated problems (e.g., cardiovascular disease [CVD]). Howev-
er, CVD co-morbidity was not excluded here, which would result
in an artificially healthy case group with beneficial lipid-
influencing genetic profiles. Information on history of myocardial
infarction was available only for 643 MRC participants (521 cases
and 132 controls).
Generalizability
The relationship between lipid metabolism and LOAD is
likely to be complex. The blood-brain-barrier prevents any
efficient exchange between brain and blood lipoproteins, and
the majority of brain cholesterol is derived from de novo
biosynthesis, rather than from blood LDL-c [40]; cholesterol
levels in the periphery may therefore not reflect brain
cholesterol levels. Additionally, although excess free cholesterol
in brain is metabolised into cholesteryl-esters, it is also
converted into 24(S)-hydroxycholesterol, an oxidized metabo-
lite of cholesterol, which crosses the blood-brain-barrier and
reaches the periphery. It has been shown that during the early
stages of AD, blood 24S-hydroxycholesterol concentrations,
which reflect TC concentrations in the brain, are high in
cerebrospinal fluid and in peripheral circulation, potentially
reflecting increased cholesterol turnover in the brain but fall in
later stages of AD suggesting a lower rate of cholesterol
metabolism as disease progresses (reviewed in [41]).
Conclusions
There is no dispute over the involvement of lipid metabolism in
the pathophysiology of LOAD. However, the results of our study
do not support a causal role for genetically increased plasma
cholesterol in LOAD and suggest that epidemiological associations
between peripheral lipids and LOAD may be confounded by
secondary disease processes. Future studies should focus on large
LOAD datasets with longitudinal peripheral lipid measures and
other markers of lipid metabolism.
Supporting Information
Figure S1 Venn diagram illustrating the overlap of
SNPs associated with the four lipid traits used in this
study. The rs4420638 SNP in the APOE locus, the SNP
rs581080 in the TTC39B locus, the SNP rs9411489 in the ABO
locus, and the SNP rs3177928 in the HLA locus are excluded.
(TIF)
Figure S2 Results of the meta-analysis pooled estimates
for the effect of a 1unit increase in blood lipid traits on
LOAD risk using instrumental variable analysis (full
genotype risk scores), using the summary method
(n=10.578*). Estimates were derived by weighing the associa-
tion between GRS and LOAD for each dataset with the
association between GRS and blood lipid using the summary
method. See Methods for further details. *Maximum.
(TIF)
Table S1 Information on SNPs used for the construction
of the genotype risk scores in this study. SNPs used for the
four GRSs constructed in this study and their association with the
respective plasma levels in Willer and colleagues [20], as well as
their association with LOAD in the three groups in this study. Risk
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allele refers to the allele associated with increasing LDL-c, TC, and
TG levels and decreasing HDL-c levels. Analyses are performed
with respect to the risk allele. Risk allele frequency refers to the
frequency of the risk allele used in the analysis. For the four full
GRSs all SNPs associated with the specific phenotype at p,561028
were used. For the trait specific GRSs only SNPs associated
exclusively with each lipid trait at p,561028 were used. The
APOE rs4420638 SNP was not included in the calculation of the
GRS because of its association with LOAD. rs581080 in TTC39B
locus, rs9411489 of ABO locus, and rs3177928 in HLA locus were
not successfully genotyped/imputed and we found no SNPs with
R2.0.8 that were successfully genotyped/imputed to be used as
proxies. *Maximum.
(XLSX)
Table S2 Association of lipid genotype risk scores with
LOAD per one unit increase in lipid levels.
(DOCX)
Text S1 Extended methods.
(DOCX)
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Editors’ Summary
Background. Currently, about 44 million people worldwide
have dementia, a group of brain disorders characterized by
an irreversible decline in memory, communication, and other
‘‘cognitive’’ functions. Dementia mainly affects older people
and, because people are living longer, experts estimate that
more than 135 million people will have dementia by 2050.
The commonest form of dementia is Alzheimer disease. In
this type of dementia, protein clumps called plaques and
neurofibrillary tangles form in the brain and cause its
degeneration. The earliest sign of Alzheimer disease is
usually increasing forgetfulness. As the disease progresses,
affected individuals gradually lose their ability to deal with
normal daily activities such as dressing. They may become
anxious or aggressive or begin to wander. They may also
eventually lose control of their bladder and of other physical
functions. At present, there is no cure for Alzheimer disease
although some of its symptoms can be managed with drugs.
Most people with the disease are initially cared for at home
by relatives and other unpaid carers, but many patients end
their days in a care home or specialist nursing home.
Why Was This Study Done? Several lines of evidence
suggest that lipid metabolism (how the body handles
cholesterol and other fats) is altered in patients whose
Alzheimer disease develops after the age of 60 years (late
onset Alzheimer disease, LOAD). In particular, epidemiolog-
ical studies (observational investigations that examine the
patterns and causes of disease in populations) have found an
association between high amounts of cholesterol in the
blood in midlife and the risk of LOAD. However, observa-
tional studies cannot prove that abnormal lipid metabolism
(dyslipidemia) causes LOAD. People with dyslipidemia may
share other characteristics that cause both dyslipidemia and
LOAD (confounding) or LOAD might actually cause dyslipi-
demia (reverse causation). Here, the researchers use ‘‘Men-
delian randomization’’ to examine whether lifetime changes
in lipid metabolism caused by genes have a causal impact on
LOAD risk. In Mendelian randomization, causality is inferred
from associations between genetic variants that mimic the
effect of a modifiable risk factor and the outcome of interest.
Because gene variants are inherited randomly, they are not
prone to confounding and are free from reverse causation.
So, if dyslipidemia causes LOAD, genetic variants that affect
lipid metabolism should be associated with an altered risk of
LOAD.
What Did the Researchers Do and Find? The researchers
investigated whether genetic predisposition to raised lipid
levels increased the risk of LOAD in 10,578 participants (3,914
patients with LOAD, 1,675 elderly people without LOAD, and
4,989 population controls) using data collected in six
genome wide studies looking for gene variants associated
with Alzheimer disease. The researchers constructed a
genotype risk score (GRS) for each participant using genetic
risk markers for four types of blood lipids on the basis of the
presence of single nucleotide polymorphisms (SNPs, a type
of gene variant) in their DNA. When the researchers used
statistical methods to investigate the association between
the GRS and LOAD among all the study participants, they
found no association between the GRS and LOAD.
What Do These Findings Mean? These findings suggest
that the genetic predisposition to raised blood levels of four
types of lipid is not causally associated with LOAD risk. The
accuracy of this finding may be affected by several
limitations of this study, including the small proportion of
lipid variance explained by the GRS and the validity of
several assumptions that underlie all Mendelian randomiza-
tion studies. Moreover, because all the participants in this
study were white, these findings may not apply to people of
other ethnic backgrounds. Given their findings, the research-
ers suggest that the observed epidemiological associations
between abnormal lipid levels in the blood and variation in
lipid levels for reasons other than genetics, or to LOAD risk
could be secondary to variation in lipid levels for reasons
other than genetics, or to LOAD, a possibility that can be
investigated by studying blood lipid levels and other markers
of lipid metabolism over time in large groups of patients
with LOAD. Importantly, however, these findings provide
new information about the role of lipids in LOAD develop-
ment that may eventually lead to new therapeutic and
public-health interventions for Alzheimer disease.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001713.
N The UK National Health Service Choices website provides
information (including personal stories) about Alzheimer’s
disease
N The UK not-for-profit organization Alzheimer’s Society
provides information for patients and carers about
dementia, including personal experiences of living with
Alzheimer’s disease
N The US not-for-profit organization Alzheimer’s Association
also provides information for patients and carers about
dementia and personal stories about dementia
N Alzheimer’s Disease International is the international
federation of Alzheimer disease associations around the
world; it provides links to individual associations, informa-
tion about dementia, and links to World Alzheimer Reports
N MedlinePlus provides links to additional resources about
Alzheimer’s disease (in English and Spanish)
N Wikipedia has a page on Mendelian randomization (note:
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
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